Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue
Up To 300 Companies Could Seek New Funds This Year
Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.
